Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06689956 · ClinicalTrials.gov registry record
Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study
A clinical trial of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 212
- Enrollment target
- 20
- Study locations
NCT06689956: Recruiting study of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, sponsored by Mayo Clinic.
NCT06689956 is a study of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 212 participants, above the 170-participant average among 5 other FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06689956, a study of FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma and FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 212 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.
Primary Outcome
RFS is defined as the length of time after primary treatment that the patient survives without any signs or symptoms of that cancer. (Recurrence may be vaginal, hematogenous, lymphatic, or peritoneal.) RFS will be measured from the date of surgery to the date of recurrence, death, or last disease evaluation.
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (20)
Other
- Medical University of Vienna - Vienna
- AC Camargo Cancer Center - São Paulo
- Institut Universitaire du Cancer Toulouse Oncopole - Toulouse
- University Hospital Essen - Essen
- Meir Medical Center, Faculty of Medicine - Tel-Aviv University - Kefar Sava
- Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale - Naples
- Hospital Materno Infantil Las Palmas - Las Palmas
- Hospital Universitario La Paz - Madrid
- Ospedale Regionale di Lugano, Civico - Lugano
MI
- Fondazione IRCCS Istituto Nazionale Tumori - Milan
- European Institute of Oncology - Milan
Minnesota
- Mayo Clinic in Rochester - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- Houston Methodist Hospital - Houston
Ontario
- Sunnybrook Health Sciences, University of Toronto - Toronto
Quebec
- Hopital Maisonneuve Rosemont - Montreal
CN
- Ospedale Michele e Pietro Ferrero - Verduno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2029-10-31 |
What NCT06689956 shows while recruiting
NCT06689956 is an observational study that tracks outcomes without assigning an intervention. The registered 212 participants enrollment target is mid-sized for trials with a published cap, above the 170-participant average among 5 other FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma trials with a reported enrollment target (25% higher).
The record links to 4 conditions, with FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06689956 names 20 study sites across 11 states, led by Other, MI, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06689956 about?
NCT06689956 is a clinical study titled "Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study". This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.
What is the current status of trial NCT06689956?
This trial is currently recruiting. The enrollment target is 212 participants. The study started on 2024-12-04. Estimated completion is 2029-10-31.
What conditions does trial NCT06689956 study?
This clinical trial studies the following conditions: FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage IA1 Endometrial Cancer FIGO 2023, Stage IA2 Endometrial Cancer FIGO 2023.
What interventions are being tested in trial NCT06689956?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06689956?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06689956 being conducted?
This trial has 20 study locations across Minnesota, New York, Texas, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients
ACTIVE NOT RECRUITING
-
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228978 · 212 participants · NA
Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
- NCT04725721 · 212 participants · NA
Testing FIRST in Youth Outpatient Psychotherapy
- NCT06257576 · 212 participants · Phase 3
Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter
- NCT06456593 · 212 participants · Phase 2
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI